Literature DB >> 2450647

Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug.

G Pizzorno1, E Mini, M Coronnello, J J McGuire, B A Moroson, A R Cashmore, R N Dreyer, J T Lin, T Mazzei, P Periti.   

Abstract

Two methotrexate-resistant sublines, CCRF-CEM R3/7 and CCRF-CEM R30/6, were selected from the human leukemia T-lymphoblast cell line, CCRF-CEM, after repeated exposures (7 and 6 times, respectively) for 24 h to constant concentrations (3 and 30 microM) of the drug. Analysis of the mechanism of resistance revealed no differences in levels of dihydrofolate reductase activity, its binding affinity for methotrexate, or in methotrexate transport between the CCRF-CEM parent and methotrexate-resistant cell lines. The development of resistance to methotrexate was associated with a marked decrease in the intracellular level of methotrexate polyglutamates. Although the resistant sublines were able to form substantial amounts of folate polyglutamates when measured with [3H]folic acid, the level of polyglutamates formed was decreased to about 50% of that formed by the parent cell line. No qualitative differences in folate polyglutamates formed were noted between the parental and resistant sublines. This is the first example of a cell line which displays resistance which is solely attributable to defective methotrexate polyglutamate synthesis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2450647

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

Review 1.  Pharmacogenomics in pediatric leukemia.

Authors:  Steven W Paugh; Gabriele Stocco; William E Evans
Journal:  Curr Opin Pediatr       Date:  2010-12       Impact factor: 2.856

2.  A human leukemia cell line made resistant to two folate analogues, trimetrexate and N10-propargyl-5,8-dideazafolic acid (CB3717).

Authors:  Y Takemura; T Ohnuma; H Miyachi; S Sekiguchi
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

3.  Amplification of the thymidylate synthase gene in an N10-propargyl-5,8-dideazafolic-acid-resistant human leukemia, MOLT-3 cell line developed in pteroylglutamic acid, but not in leucovorin.

Authors:  H Miyachi; Y Takemura; H Kobayashi; Y Ando
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

4.  Site-directed mutagenesis establishes cysteine-110 as essential for enzyme activity in human gamma-glutamyl hydrolase.

Authors:  K J Chave; J Galivan; T J Ryan
Journal:  Biochem J       Date:  1999-11-01       Impact factor: 3.857

5.  Novel pyrrolo[2,3-d]pyrimidine antifolate TNP-351: cytotoxic effect on methotrexate-resistant CCRF-CEM cells and inhibition of transformylases of de novo purine biosynthesis.

Authors:  F Itoh; O Russello; H Akimoto; G P Beardsley
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies.

Authors:  Garry H Schwartz; Christopher B Jones; Mitchell Garrison; Amita Patnaik; Chris Takimoto; Heather McCreery; Michael Skinner; Anthony W Tolcher; Eric K Rowinsky
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

Review 7.  Clinical pharmacokinetics and pharmacology of trimetrexate.

Authors:  J L Marshall; R J DeLap
Journal:  Clin Pharmacokinet       Date:  1994-03       Impact factor: 6.447

8.  Tissue localization of methotrexate-monoclonal-IgM immunoconjugates: anti-SSEA-1 and MOPC 104E in mouse teratocarcinomas and normal tissues.

Authors:  B Ballou; R Jaffe; S Persiani; W C Shen; J J Langone; H Sands; J M Reilandu; J Curley; T R Hakala
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

9.  The role of folates in the development of methotrexate resistance in human leukemia cell line K562.

Authors:  H Miyachi; Y Takemura; Y Ando; K J Scanlon
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

10.  Effects of folylpolyglutamate synthetase modulation on chemosensitivity of colon cancer cells to 5-fluorouracil and methotrexate.

Authors:  K-J Sohn; F Smirnakis; D N Moskovitz; P Novakovic; Z Yates; M Lucock; R Croxford; Y-I Kim
Journal:  Gut       Date:  2004-12       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.